PRESS RELEASE
Pharmaterials Ltd and PII (Pharmaceutics International, Inc.) have formed an alliance. This association will extend the business development initiatives and increase the value of the service offerings of both companies.
PII, a leading provider of formulation development and cGMP manufacturing services, will market Pharmaterials in the US and Pharmaterials will market PII in Europe.
Steve King, Senior VP of PII stated “PII offers a very wide range of cGMP production and formulation development services which have been expanded through alliances in drug delivery ventures. This collaboration with Pharmaterials will enable PII to provide a complete service for our customer base. We have a very high regard for Pharmaterials and are pleased to offer their services to our customers in a seamless approach. This is a great fit for the two companies and will add value in the service offering that we can provide together.”
Professor Graham Buckton, Chief Executive and founder of Pharmaterials, said “PII is a company that provides an excellent service to their wide client base. They have a state of the art facility with a staff of over 300 providing formulation and manufacturing services. The success that they have seen is based on providing value to their customers, which is the same philosophy at Pharmaterials. Working together we will be able to provide preformulation, polymorphism, salt screening and co-crystal services to PII’s existing customers. In addition, we can provide new options in cGMP transfer to enhance our own services. I am excited about this collaboration and the benefits that it will bring.”
PII (www.pharm-int.com) is a contract formulation development, Clinical Trail Materials (CTM) and commercial manufacturing company based in Hunt Valley, Maryland. Founded in 1994, PII can manufacture most solid and semi-solid dosage forms for use in clinical trials and commercial sale. These services are complemented by full analytical and regulatory support. The 170,000 square foot cGMP facility contains on-site manufacturing suites, analytical laboratories and 30,000 square feet of additional warehouse space. The company has a balanced client base of major multinational and virtual pharmaceutical companies that are primarily focused in the United Sates and Europe.
Pharmaterials Ltd (www.pharmaterials.co.uk) is a technology driven contract research organization specializing in the optimization of drug substance physical forms and formulations to facilitate the development of low solubility and poorly permeable drug substances. With partnerships that span the globe, Pharmaterials works with a range of organizations including start-up, mid-size and multinational companies. Founded in January 2000 by Professor Graham Buckton, the company has exponentially expanded through implementation of an organic business model. Pharmaterials is housed in state-of-the-art laboratories and offices in Reading, UK and has offices in Tokyo. |
